Graft versus leukemia effect of FasL-modified dendritic cells and its mechanism

WANG Mei-ling,LIU Feng,JIANG Bin,LOU Guo-liang,ZHANG Wen-ying,HU Xiao-hua,GONG Yu-fang,YUAN Hai-hua,WANG Jiong-yi
DOI: https://doi.org/10.3872/j.issn.1007-385X.2007.06.006
2007-01-01
Abstract:Objective: To specifically inhibit the graft versus host disease(GVHD) and keep graft versus leukemia(GVL) effect of bone graft through selective deletion of alloreactive lymphocytes from haematopoietic stem cell grafts.Methods:BALB/c mice dendritic cells genetically engineered to express FasL were cultured with C57BL/6 mice stem cell grafts,and the pretreated stem cell grafts were used in a C57BL/6 to BALB/c mice GVHD/leukaemia model system(H-2bH-2d).Untreated stem cells and those with T lymphocytes deleted were taken as controls.Then the survival of mice was observed and compared.51Cr release test was used to determine CTL activity of recipient mice 2 month after transplantation.Results: Mice receiving donor haematopoietic stem cell grafts pretreated with FasL-DC did not develop GVHD after lethal dose irradiation(9 Gy) and their survival period was greatly prolonged,with the survival rate being 40% after 2 months; mice in the control groups all died in 30 day.Result of 51Cr release test showed that in FasL-DC group T cell had strong cytoxicity on P815 cells.Conclusion:DC transfected with FasL gene can effectively remove alloreactive T lymphocytes in bone marrow graft.The bone marrow treated with this kind of technique can not only inhibit GVHD but also keep the GVL effect of haematopoietic stem cell grafts.
What problem does this paper attempt to address?